DDInter379 DDInter1763
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Cilostazol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Cilostazol {u} (Compound) downregulates {v} (Gene) TRIB3
TRIB3 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Cilostazol {u} (Compound) upregulates {v} (Gene) MAL
MAL {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Cilostazol {u} (Compound) downregulates {v} (Gene) CLTB
CLTB {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Cilostazol {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Cilostazol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Cilostazol {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) covaries with {v} (Gene) YRDC
YRDC {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Cilostazol {u} (Compound) downregulates {v} (Gene) TRIB3
TRIB3 {u} (Gene) interacts with {v} (Gene) SETDB1
SETDB1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Cilostazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Cilostazol (Compound) downregulates TRIB3 (Gene) and TRIB3 (Gene) is upregulated by Temsirolimus (Compound)
Cilostazol (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Temsirolimus (Compound)
Cilostazol (Compound) downregulates CLTB (Gene) and CLTB (Gene) is downregulated by Temsirolimus (Compound)
Cilostazol (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Temsirolimus (Compound)
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Cilostazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Cilostazol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) covaries with YRDC (Gene) and YRDC (Gene) is downregulated by Temsirolimus (Compound)
Cilostazol (Compound) downregulates TRIB3 (Gene) and TRIB3 (Gene) interacts with SETDB1 (Gene) and SETDB1 (Gene) is upregulated by Temsirolimus (Compound)